Categories: Technology

PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025

Press Release

Evolution of PROACTIS SA Governance

PARIS, France – (19 December 2025) — Under the terms of the Board of Directors of the company PROACTIS SA (ISIN code: FR0004052561) held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning.

Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in our next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan.

During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning.

Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution.

Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31st, 2026.

As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows:

Member Functions Mandate expiry date
Andrew REARDON Chairman of the Board of Directors
Chief Executive Officer
Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Charlotte CARTER Director Annual General Meeting to approve the financial statements for the year ending January 31, 2030
Peter SHEPHERD Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Maria LARSEN Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028

* * * *

Contacts
Tel: +33 (0)1 53 25 55 00
E-mail: investorContact@proactis.com

* * * *

GlobeNews Wire

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

58 minutes ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

58 minutes ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

59 minutes ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

59 minutes ago